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Compliance to GMP guidelines for Herbal Manufacturers in East
Africa: A Position Paper
V. Kwesiga1, Z. Ekeocha2, S. Byrn3, K. Clase4 
ABSTRACT
With the global increase in the use of traditional and complementary remedies for the prevention and treatment
of illness, the quality and safety of these medicines have become a significant concern for all regulatory
authorities. Herbal medicines are the most commonly used form of traditional and complementary medicines
in the world and the efficacy and safety of herbal medicines, like conventional medicines, largely depends on
their quality from planting to harvesting, preprocessing and final processing.
Due to the inherent complexity of herbal medicines, often containing an array of active compounds, the
primary processing of herbal medicines has a direct influence on their quality. Quality concerns are the reason 
why the medicines regulatory agencies insist that manufacturers of medicines strictly follow Good
Manufacturing Practices since it is an essential tool to prevent instances of contamination, mix-ups, deviations,
failures and errors. However, a strict application of GMP requirements is expensive and would drive the prices
of the manufactured products up. As a result, a maturity level grading of facilities is proposed as a way of
justifying the costs incurred for manufacturers desiring to reach a broader market and investing in continuous
improvement.
36 Good Manufacturing Practice (GMP) inspection reports of local herbal manufacturers conducted by
National Drug Authority were analyzed to establish the type and extent of deficiencies to GMP requirements
for local herbal manufacturers in Uganda. The different GMP chapters and related sub-parameters constituted
the variables used for the analysis of conformity to requirements. The primary outcome variable was the
conclusion regarding compliance or noncompliance of the inspected local herbal manufacturing facility. GMP
parameters that were frequently defaulted by local herbal manufacturers and the corresponding frequencies
were identified. The Pearson Chi-square test was applied independently on each category to find the association that
existed between conformity and the questions in each category.
Only 22% (8) of the 30 inspected facilities were found to comply with GMP requirements, as per National
Drug Authority (NDA) guidelines; while the majority of the facilities, 28 (78%), were found not to comply.
Of the facilities inspected, 25 were undergoing GMP inspection for the first time. A total of 1,236 deficiency
observations were made in the 36 inspection reports reviewed for the study. The mean for all deficiencies was
34.3, and the standard deviation was 15.829. 91.5% of the facilities did not have mechanisms for a record
of market complaints; 80.9% did not meet documentation requirements; 78.9% did not have quality control
measures in place, and 65.7% did not meet stores requirements.
By encouraging a culture of self/voluntary improvement through the introduction of listing of manufacturers
based on a maturity level grading, the National Drug Authority will improve the Herbal Medicines sector as
per the mandate of improving the herbal medicine industry. Also, increased sensitization of all relevant
stakeholders regarding the requirements for GMP should be intensified.
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Engineering, Purdue University
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1. INTRODUCTION
1.1. Historical Perspectives of Traditional Medicines
Traditional and complementary remedies have been
deeply embedded in the lifestyle of ancient peoples
and have been employed in the prevention and
treatment of illness (Lemonnier, 2017). Traditional
and complementary medicine is a vital health resource
in the prevention and treatment of chronic diseases
of the ever-ageing world populations (World Health
Organization, 2019b). Natural products have provided
good medicinal leads in search of new medicinal
compounds. Several well-known medicines that are
currently in use are derived from plant sources such
as Artemisinin, Quinine, Vincristine and Aspirin.
The most frequent sources of traditional medicines
are herbal, but animal and mineral materials are also
sources. Mahomoodally considers Africa to be the
cradle of humankind due to its abundant biological
and cultural diversity, especially regarding differences in
healing practices (Mahomoodally, 2013).
1.2. EAC Potential for the Development of Traditional
Medicine
East Africa will greatly benefit from investing in the
development of its traditional medicine as a source
of foreign exchange earnings and as an alternative to
contemporary medicine in solving the public health
challenges that the region is currently tackling. (East
African Community, 2017) As of 2008, the traditional 
medicines global market stood at about USD 83 
billion annually and continues to increase. (East
African Community, 2017) Indeed, with about 40,000
to 45,000 species of plants with a potential for
development, only 5,000 species have been used
medicinally. With such biodiversity, Africa has great
potential that is still unutilized and waiting to be
discovered (Mahomoodally, 2013). However, the
most significant danger to this enormous potential is
the rapid loss of most of these natural plant habitats
as a result of human activities. With very high rates of 
deforestation reported at 0.7% per annum, there isa 
need to regulate the preservation of these species
(FAO, 2006). Besides, there has been a rapid loss
of valuable traditional knowledge due to lack of
permanent documentation of these remedies in Africa
(Mahomoodally, 2013).
The World Health Organization (WHO) policy on
traditional medicine aims to facilitate countries to
develop strategies to make traditional medicine part
of their national health care systems (World Health
Organization, 2013). However, previous works in
other countries and healthcare fields reveal many
challenges facing this proposed integration of
traditional medicine into mainstream national health
care systems (Kayombo et al., 2007).
Like the WHO policy on traditional medicines, the
Uganda National Health Policy 2015 provides for
maximization of the benefits of Traditional and
Complementary Medicines (TCM) and protection of
the public against their possible adverse effects. The
achievement of this objective depends on establishing
and operationalization of an appropriate structure to
promote, coordinate and monitor the implementation
of multi-sectoral traditional and complementary
medicines activities in Uganda (MOH, 2015).
Likewise, the National Drug Authority (NDA),
established by the National Drug Policy and Authority
Statute in 1993, is mandated to encourage and facilitate
research and development of herbal medicines in the
country. Section 41(1) of the National Drug Policy
and Authority (NDP/A) Act, Cap. 206 states that “The
National Drug Authority shall encourage research by
persons carrying on research and development in
herbal and other medicines and, where appropriate,
take such medicines into production as a component
of the drug supply” (National Drug Policy and
Authority Act, 1996).
1.3. Good Manufacturing Practices in Herbal Medi-
cine Manufacture
The inherent complexity of the composition of herbal
medicine, consisting of tens of compounds, along with
the number and small quantity of well-defined active
ingredients, make Good Manufacturing Practices an
essential tool to assure the quality of herbal medicines.
The WHO recognizes that the production and primary
processing of herbal medicines critically determines
the quality of the finished product (World Health
Organization, 2007).
Good manufacturing practices are those control
measures that ensure which products are produced
and controlled in conformance with quality standards
fitting to their intended use and as required by the
marketing authorization (PIC/S, 2013; World Health
Organization, 2011). The manufacturing process is






     
      
       
    
  
  
       
      
  
  
       
 
 
       





   
        
        
  
 
      
 
 
   
 
 
        
       
        
      
        
  
       
 
 
         
 
          
        






     
      




         
       
 
 
      
     
      





        
     
 
      
 
 
        
        
       
      
      





   
      
 
 
      
 
         
 
 
       
 




      
 
        
medicinal products, including herbal medicines.
It has been demonstrated that when manufacturers of
medicines adopt GMP controls, they produce
medicines with the expected identity, strength, quality
and purity (U.S. Food & Drug, 2020). Manufacturers
are expected to buy and use quality raw materials for
the production of medicines. They are also expected
to establish standard operating procedures to be
meticulously followed during production with no
process steps skipped. They should have systems to
detect and investigate product quality deviations and
maintain reliable testing laboratories. The reason why
regulatory bodies demand strict adherence to these
practices is to prevent instances of contamination,
mix-ups, deviations, failures and errors (PIC/S, 2013;
World Health Organization, 2013).
1.4. Adverse Drug Reactions Due to Herbal Medi-
cines
The public generally believes that herbal medicines
are very safe and devoid of adverse effects because
they are found in nature. However, studies have
shown that herbs are capable of producing many
undesirable reactions. Ekor demonstrated that some
of these herbal remedies had caused severe injuries,
life-threatening conditions and even death. Many
irrefutable cases of poisoning as a result of intake of
herbal remedies have been reported in the literature
(Ernst, 2002). Auerbach et al. (2012) reported an
association between traditional herbal medicine use
and the development of liver fibrosis among study
participants in Uganda (Auerbach et al., 2012). In
most countries, manufacturers or importers sell herbal
medicines and related products into the market without
any mandatory safety or toxicological evaluation.
Since very few people using herbal medicines inform
their primary care physicians, many adverse drugs
reactions likely go unrecorded (Ozioma & Okaka,
2019).
There are direct and indirect causes of adverse events
arising from the use of herbal medicines. Some herbs
have been shown to have intrinsic toxicity at the usual
therapeutic dosage, or in overdose. Other adversedrug
reactions are caused by contamination with toxic
metals, other adulteration or by substitution of herbal
ingredients or improperly produced products (Zhang
et al., 2012) and wrong indications and herb-drug
interactions (Zhang et al., 2015).
1.5. Substandard and Falsified Products
WHO and other international organizations have
recognized the circulation of substandard and
falsified medicines as a global problem affecting all
medicines, medical consumables, lifestyle products,
as well as herbal medicines. Ernst has reported an
increase in the rate of adulteration of herbal medicine
with extraneous chemical substances or banned drugs
(Ernst, 2002).
Herbal medicines are adulterated with undeclared
drugs/chemical substances, together with being
substituted with non-drug components and other
foreign non-drug materials. Some manufacturers have
been found culpable for intentional adulteration(Xu, 
et al., 2019). Between 2007 and 2016, Tucker
reported that 776 dietary supplements marketed for
sexual enhancement, weight loss or muscle building
in the United States of America contained unapproved
pharmaceutical ingredients (Tucker et al., 2018).
The National Drug Authority surveyed herbal
products claimed to enhance sexual activity in the
central division of Kampala to isolate and identify
adulterants. A total of 49 samples was randomly
collected and screened for the presence of adulterants.
75% of imported herbal products contained unreported
added conventional medicine, whereas the prevalence
of adulteration for locally manufactured herbal
products was 49% (National Drug Authority, 2020b).
These reports show the high rate of counterfeiting of
these products due to the lack of rigorous checks as
compared to conventional medicines.
1.6. Study Justification
Although adherence to Good Manufacturing Practices
(GMP) is a crucial step in ensuring the quality of
herbal medicines, conforming to GMP requirements
requires investment from manufacturers. It is
estimated that small manufacturers would have to
incur 7.2% of annual income to establish and maintain
GMP requirements which eventually impacts on the
affordability of the medicines (InstantGmp, 2002).
Therefore, strict adherence to all parameters in
standard GMP guidelines may not help the National
Drug Authority achieve its mandate of encouraging
research and development of herbal medicines.
The overall objective of the study was to determine
compliance with GMP guidelines for herbal
manufacturers in Uganda. The aim was to determine









   
       
    
       
      
     
  
        
    
 
        
 
       
      









         
        
        
   
  
          
     
   
  
      
      
     
      
      
       
       
        
      
   
 
  
   
  
    
    
  
   
  
   
 
 
       
 
    
  




      
       
      
       
 
   
        
  
 
      
 
1 • Rate of Compliance to Good Manufacturing practices (GMP) 
requirements by Local herbal manuacturers in Uganda 
■ Does not conform to requirements 
■ Conform to requirements 
manufacturers and propose a risk-based framework
for maturity grading of local herbal manufacturers.
2. METHODOLOGY
2.1. Research Design
The study used a literature review   research design
through an assessment of existing Good 
Manufacturing Practice inspection reports forlocal
herbal manufacturers in Uganda conducted by
National Drug Authority. The study was both 
descriptive and analytical. The descriptive approach
focused on the quantitative aspect of the study that
involved obtaining information regarding the
parameters of GMP evaluated as provided for in the
GMP guideline currently in use for inspection of local
herbal manufacturers. The analytical part evaluated
the current practice compared with other NRAs.
Adaptation of these GMP parameters to the country’s
situation and level of sophistication of the majority of
the local manufacturers were made in order to realize
the mandate of NDA in improving the standards of
locally manufactured herbal medicines.
2.2. Study Population
The study focused on reports generated from GMP
inspections of local herbal manufactures in Uganda.
The study population included all manufacturers who 
had undergone GMP inspection by the time this study
was conducted. A total of 36 reports were included in
the analysis. All completed GMP reports of previous
inspections of local herbal manufacturers in Uganda
were obtained from the NDA repository and included
in the study.
2.3. Data Collection Methods
The secondary data for this study was obtained from
the completed GMP inspection reports. Variables were
identified by the different aspects contained in the
National Drug Authority GMP inspection checklist
containing the different GMP parameters considered
by the GMP inspectors. The data obtained from these
reports were collected using a Microsoft Access
database designed for this purpose. The different
GMP inspection reports were coded to enable quicker
cross-referencing of data captured in the database to
ensure the validity of data captured. The outcomes of
the inspection exercise were also captured in the same
Access database.
2.4. Reliability of the Research Instruments
Cronbach’s alpha was used to test the internal
consistency of the checklist used to assess GMP for
local herbal manufacturers which was the basis for the
reports included in the study. It was found that thetool
was highly reliable (Cronbach’s alpha=0.95).
2.5. Data Analysis
The primary outcome variable was the conclusion
regarding compliance or noncompliance of the
inspected local herbal. Different activities carried out
by inspected facilities included cultivation of
medicinal plant materials, manufacture of herbal
medicine, packaging and importing. Their frequencies
were determined using SPSS/20. The GMP inspection
checklist titles/chapters were used to identify the
GMP parameters that are frequently defaulted bylocal
herbal manufacturers. These constituted the measures
of conformity and are categorized into ninegroups
including;
• Premises
• Location and surroundings
• Stores
• Sanitation and hygiene









   
  
        
    
 
     
     
   
     
  
 
     
      
      
       
       





        
 
  
      
       
    
   
    
  
    
    
  
   








          
  
 
    
   
     
 
         
 
   




      
   
 
       
  
  
        
          
       
  
       
        
     
       
       
  
        
           
   
     
    
  
   
    
  
  











Tablets - 4% 
0% 5% 10% 15% 20% 25% 30% 35% 40% 45% 50%
Activity Inspection reports associated
with the activity
Yes, n (%) No, n (%) Total
Cultivation of medicinal plant
materials
10 (27.8) 26 (72.2) 36
Collection and storage of me-
dicinal plant material
23 (63.9) 13 (36.1) 36
Manufacture of herbal medi-
cine
32 (88.9) 4 (11.1) 36
Packaging 24 (66.7) 12 (33.3) 36
Importing 5 (13.9) 31 (86.1) 36
Laboratory testing 2 (5.6) 34 (94.4) 36
Table 1: Activities carried out by facilities
Pearson Chi-square test was applied independently
on each category to find the association that existed
between conformity and the GMP parameters within
each category.
The significant factors were selected and subjected to
binary logistic regression to determine their
relationship with non-conformity. The primary
outcome of this model was “not conform=1” and
“conforms=0”. Crude odds ratios (core) and p-values
with a statisticalsignificance of 0.05 were presented at
the bivariate level. A multivariable logistics
regression was used to determine independent
variables significantly associated with non-
conformity, adjusting for relatedfactors and potential
confounders. Based on the likelihood-ratio (LR), a 
stepwise forward selection was used to find
significant variables, retaining thosevariables with p-
values < 0.2. The adjusted odds ratios and their p-
values were reported. The conclusions on the 
significance of the relationships were based on a 5%
level of significance.
3. RESULTS
Figure 2: Dosage forms manufatured by the local herbal manufacturing facilities
Oral Solutions


















The National Drug Authority had inspected thirty
local herbal manufacturing facilities by the time of
the review. Of these, 69.4% of facilities were being 
inspected for the very first time. Only 23% (7) of
the inspected facilities fulfill the requirements for
compliance to GMP specifications as per National
Drug Authority guidelines. In comparison, the
majority of the facilities 77% (23) do not comply with
the requirements, as shown in Figure 1.
Overall, the most frequently carried out activity by the
facilities was the manufacturing of herbal medicine
(n=32, 88.9%), followed by packaging (n=24, 66.7%)
and collection and storage of medicinal plant material
(n=23, 63.9%) as shown in Table 1. The least carried
out activity was laboratory testing (n=34, 94.4%),
followed by importing (n=31, 86.1%) and cultivation
of medicinal plant materials (n=26, 72.2%) as
summarized in Table 1.
Oral solution dosage forms were manufactured in44%
of inspected facilities, followed by liquids for external
use in 13% of inspected sites. Creams and ointments
were third at 11%. Results for other dosage forms
covered in the inspection are shown in Figure 2. In
addition, results show that only 27.8% of surveyed
reports correspond to facilities engaged in cultivation 
of the raw materials used for the production of the
herbal medicines. Evidence needs to be gathered
to demonstrate whether the manufacturers of the raw
materials (API) adhere to Good Agricultural
Practices. These manufacturers would have to be
certified to conduct this cultivation process according
to the set requirements to facilitate traceability. It is




      
 
      
  




        




   
      
 
    
       
 
 
           
 
   
 
 
        
  
      
       
    
 
    
        




      
 
        




       
 
        
        
     
 




        
  
      
        
   
 
       
  
     
  
    
  
          
     
   
 
         
     
  
   
  
    
   
    
  
    
 0.0% 10.0% 20.0% 30.0% 40.0% 50.0% 60.0% 70.0% 80.0% 90.0% 100.0%
have contracts with raw material suppliers.
3.1. Deficiencies Observed in the Review
1,236 deficiencies were observed in 36 inspection
reports reviewed. The average number of deficiencies
was 34.3 per report, with a standard deviation of
15.829 deficiencies. 91.5% of the facilities did not
have mechanisms for record of market complaints.
There was an 80.9% rate of noncompliance to
P=0.042), as summarized in Table 2.
Firms with no suitable weighing areas for materials
were approximately eight times more likely not to
conform to GMP standards (aOR=7.71, P=0.012). 
Firms with no appropriate weighing scales were
approximately nine times more likely not to conform
to GMP standards (aOR=9.21, P=0.0002). Firms
whose scales were not calibrated regularly were
Figure 3: Rate of nonconformance to GMP requirements per inspection parameter
documentation requirements, 78.9% noncompliance




Machinery & Equipment 62.7%
Production area 61.8%
Sanitation and Hygiene 41.5%
Premises 33.1%
Location & surroundings 9.5%
to quality control requirements and 65.7% rate of
noncompliance to requirements for stores, as shown
in Figure 3. These results indicate that very few
products manufactured by the local manufacturers
would meet any international standards since the
three key control areas: stores, production and quality
control areas have the highest deficiencies.
3.2. Logistic regression results
Logistics regression results are summarized in Table 2.
Firms without adequate space for equipment, materials
and movement of personnel were approximately five
times more likely not to conform to GMP standards
(aOR=4.81, P=0.001). Firms whose premises were
not constructed to allow adequate cleaning, good 
sanitation and hygiene practices were seven times
more likely not to conform to GMP standards
(aOR=7.12, P=0.041). Firms whose premises had
no logical flow of activities, material and personnel
were two times more likely not to conform to GMP
standards (aOR=2.31, P=0.002). Firms whose raw
materials or ingredients were not identified, inspected
and tested before processing were six times more
likely not to conform to GMP standards (aOR=6.14,
approximately eight times more likely not to conform
to GMP standards (aOR=8.31, P=0.031). Firms whose
area for weighing was not frequently and adequately
cleaned were five times more likely not to conform
to GMP standards (aOR=5.61, P=0.028). Firms with
no straightforward and illustrative procedure listing
the required basic personal hygiene practices were
approximately seven times more likely not to conform
to GMP standards (aOR=5.61, P=0.001). Firms with
no running water for handwashing after use were
approximately 12 times more likely not to conform to
GMP standards (aOR=11.91, P=0.021).
Firms whose personnel were not protected from
contact with toxic irritants and potentially allergenic
plant materials using adequate protective clothing 
were approximately nine times more likely not to
conform to GMP standards (aOR=8.81, P=0.031). 
Firms whose batch manufacturing records were not
kept for all batches were five times more likely not
to conform to GMP standards (aOR=5.31, P=0.0016). 
Firms whose record of sale and distribution of each
batch of alternative medicines were not maintained









       
         
      
 
         
  
  
          
 
      
  
 
    
 
    
 
  
       
      















        
  
  
      
 
        
 
         
 
        
   
       
 
      
        
 
       
  
  
   
   
 
        
         
      
       
       
  




       





        
        
       
 
  




      
      
 
     





       
 
 
        
  
        
standards (aOR=12.31, P=0.031) as shown in Table 2.
Firms whose production area was not adequate to
carry out production activities were eight times more
likely not to conform to GMP standards (aOR=8.05,
P=0.041). Firms whose personnel do not wear
protective gear were six times more likely not to
conform to GMP standards (aOR=6.21, P=0.045).
Firms whose final products were not sampled batch-
wise for quality testing before being released were nine
times more likely not to conform to GMP standards
(aOR=9.21, P=0.003). Firms with no quality control
laboratory were 13 times more likely not to conform to
GMP standards (aOR=13.01, P=0.014). Firms whose
final product was incorrectly labelled, including the 
expiry date, were eight times more likely not to
conform to GMP standards (aOR=8.51, P=0.031) as
summarized in Table 2.
4. DISCUSSION AND PERSPECTIVES
4.1. Demographics
The facilities included in the study mostly
manufactured oral solutions (44%), followed by
liquids for external use (13%) and then creams and
ointments (11%). Figure 2 shows that most of the
herbal medicines produced by local manufacturers in
Uganda are intended for ingestion. This corresponds
to a report by Kumadoh and Ofori-Kwakye (2017)
that identified oral solutions, also known as
decoctions. These solutions were prepared by boiling
the herb in water for a specific time. They were the
most common dosage forms produced by his study
group in Nigeria. These preparations usually were
recommended to be used immediately within 24 to 48
hours.(Kumadoh & Ofori-Kwakye, 2017) However,
Kumadoh notes that the proliferation of large-scale
production has led to increased shelf-life for herbal
products without review of stability data.(Kumadoh
& Ofori-Kwakye, 2017) The absence of stability data
and the generic expiry dates of 1-3 years poses a risk
to patients who buy these products as the products
may have deteriorated and contained unidentified
breakdown products not intended for consumption.
(European Medicines Agency, 2007) It is important to
note that the herbal preparations manufactured and
sold in Uganda are subject to a simplified registration
process called “notification”. Stability data for local
herbal remedies is not required for submission before
approval for sale is granted.
4.2. Rate of Compliance to GMP Guidelines
GMP is aimed at ensuring that products are produced
and controlled according to required quality
appropriate to their intended use and as approved
by the marketing authorization. For the 30 facilities
inspected, only 23% (7) facilities were considered
to fulfill the requirements for compliance with GMP
guidelines for herbal manufacturers in Uganda. In
contrast, the majority of the facilities, 77% (23), did
not comply with the requirements.
The majority of manufacturers rely solely on the
experience of the lead herbalist to ensure thatthe
product is sufficiently produced. Large scale
production requires scale-up and validation of smaller
traditional processes, which are the experience ofthe 
lead herbalist. This poses a risk of magnifying errors
arising from scaling up runaway processes thataffect
the quality of the finished products. As a result, these
products cannot comply with intra and inter batch 
organoleptic, or chemical consistency tests like
powder fineness, foreign matter and aflatoxin content.
Therefore, patients will be exposed to different
quantities and contents of the drug possibly resulting
in overdose or under-dose.
4.3. Non-conformances
Overall, 1,236 deficiencies were made in the 36
inspections reviewed for the study. The number of
deficiencies per facility averaged 34.3 ± 15.8
deficiencies. This is a very high level of deficiencies
observed per facility, with almost half the parameters
inspected being identified as nonconformances. One
reason for this high level of nonconformance
observations seen in the reports reviewed may have
been the high cost required for implementation and
maintenance of GMP requirements in a resource-
limited setting. Typically, small manufacturers would
have to incur 7.2% of annual income to establish and
maintain these requirements (InstantGmp, 2002).
With rudimentary techniques of manufacture and low 
incentives for venture capital investments, it is
difficult for small manufacturers to afford this high
level of investment.
Also, a lack of knowledge of GMP requirements
could have been a factor in explaining these results
since 69.4% (25) reports reviewed in the research
were for first-time inspections. Only 31.6% of reports
were for subsequent inspections. The National Drug





       
      
   
      
      
      
   
    





      
   
  
         
         
   
  
  





        
     
      
 
     
 
 
       
 




           





         
        
  
     
        
 
 
      
     
          
      
       
  
      
   
 
      
      
 
   
 
      
  
    
      
     
 
  




       
     
      
   
      
     
   
 
      
  




   
      
      
  
     
  
 
GMP inspection framework within the organization.
Training of inspectors to conduct inspections and
education of herbal manufacturers regarding the
regulator’s expectations has begun NDA.
4.4. Most Relevant Areas of Deficiency
Among the parameters inspected for Good
Manufacturing Practices, absence of mechanisms for
recording of market complaints, noncompliance to
documentation requirements, quality control
requirements and requirements for stores had
significantly more noncompliant GMP observations
than other parameters. 91.5% of the facilities did not
have mechanisms for record of market complaints.
According to the WHO, all product complaints, and
potentially defective products, should be carefully
investigated to identify the root cause according to
written SOPs; and the corrective action should be
taken. This is an essential aspect of GMP because
the review of complaints could reveal that the product
was actually defective and that regulatory action
needs to be taken. In addition, this presents a learning 
opportunity for the manufacturer to improve the
product. When defects are detected, measures are put
into place to ensure that they do not recur, hence 
saving money that would otherwise be used to
withdraw or rework the product.
There was an 80.9% rate of noncompliance to
documentation requirements. The requirement for
documentation aims to define the specifications and 
procedures for all materials and manufacturing
process and quality control. Documentation requirements
ensure that all employees know what to do and when
to do it and ensure that before release of a batch for
sale, authorized persons have all the information
necessary to release of reject the batch. Documents
provide records of an audit trail that will permit
investigation in case of product failure or product-
related complaints. (National Drug Authority, 2020a)
Quality control ensures that relevant tests are carried
out and that materials are released for use, or sale only
after ascertaining that their quality complies with the
requirements. There was a 78.9% noncompliance to
quality control requirements.
A 65.7% rate of noncompliance to requirements for
storage areas was observed in the study. Storageareas
are expected to have sufficient capacity to allow
orderly storage of materials and products, withproper
separation and segregation. Sufficient storage
areas ought to be provided, controlled, monitored and
recorded, as required for manufacturing and control
task.
4.5. Most Relevant and Scientific Associations
Significant correlations were observed between
failure to comply with these 4 of the 9 categories
of GMP parameters (independent variables) and
failure to comply with GMP requirements (dependent
variable outcome). These include production areas,
preparation of materials for production, personnel
issues, and quality control deficiencies.
Among the parameters inspected for Good
Manufacturing Practices for production areas, lack
of adequate production space (aOR=4.81, P=0.001),
designs which do not allow for adequate cleaning
(aOR=7.12, P=0.041) and logical flow of materials
(aOR=2.31, P=0.002) were significantly more critical
in predicting failure to comply with GMP
requirements. Unsuitable (aOR=7.71, P=0.012)and
dirty weighing areas (aOR=5.61, P=0.028), together
with inappropriate (aOR=7.71, P=0.012) and
uncalibrated weighing scales (aOR=9.21, P=0.0002),
were significantly more critical in predicting failure to
comply with GMP requirements among GMP
parameters related to the preparation of materials for
manufacturing of products.
Likewise, among the parameters inspected for Good
Manufacturing Practices affecting personnel issues,
lack of running water for handwashing (aOR=11.91, 
P=0.021), lack of protection of workers from toxic
materials (aOR=8.81, P=0.031) and absence of
protective gear (aOR=6.21, P=0.045) were
significantly more critical in predicting failure to
comply with GMP requirements. For parameters
affecting documentation, the issues most significantly
predicting failure to comply with GMP include lack
of traceability mechanisms like keeping of batch
records (aOR=5.31, P=0.0016), and lack of sale and
distribution records (aOR=12.31, P=0.031). Lastly,
among the parameters inspected for Quality Control,
lack of proper quality control mechanisms like the
batch-wise sampling of finished products (aOR=9.21,
P=0.003), lack of QC laboratory (aOR=13.01,
P=0.014) and incorrect labelling of finished products
(aOR=8.51, P=0.031) were significantly more





                 
 
    
 
 
          
 
               
       
 
 
    
   
     
 
 
               
    
 
 
        
    
 







       
       
   
   





    
 
        
        
       
 
       
     
       
  
        
         
       
  
          
        
 
      
 
    
       
         
        
  
  
      
  
  
   
   
   
        





    
       
 
       
 
   
 






         
      
  
        
 
   
       
      
    
     
Table 2: Criteria for assigning maturity level (This model is adopted from WHO Global Benchmarking Tool (GBT)
Maturity Level Risk Rank Description
Maturity Level 1
(ML1)
High All GMP parameters that are ranked HIGH risk would constitute the Maturity Level 1
(ML1) and are considered essential for being listed at all after assessment. Omitting
any if these requirements constitutes a high risk to the final consumer since this cannot
guarantee a good and consistent quality product.
Maturity Level 2
(ML2)`
Medium All GMP parameters ranked as MEDIUM risk would constitute the Maturity Level 2
(ML2), with an evolving quality management system that partially performs essential
GMP functions as regards Herbal products.
Maturity Level 3
(ML3)
Low All GMP parameters ranked as LOW risk would constitute Maturity Level 3 (ML3), with
a stable and functioning GMP system
Discovery of the leading GMP deficiencies is a
crucial step for regulatory authorities to identify the
root causes of medicines-related issues and prioritize
when allocating resources to improve the industry.
It is useful to adopt an annual review on common
GMP deficiencies to identify high-risk GMP areas for
training, and identifying the GMP inspections to high-
risk facilities. (PIC/S., 2013)
4.6. Framework for Maturity Level Grading
The World Health Organization developed the Global
BenchmarkingTool (GBT)usedtoobjectivelyevaluate
regulatory systems. The GBT also incorporates the
concept of ‘maturity level’ or ML (adapted from ISO
9004), allowing WHO and regulatory authorities to
assess the overall ‘maturity’ of the regulatory system
on a scale of 1 (existence of some elements of the
regulatory system) to 4 (operating at an advanced
level of performance and continuous improvement).
(World Health Organization, 2019a).
A similar framework has been developed and is
proposed for use during the evaluation of compliance
of Good Manufacturing Practices for local herbal
manufacturers in Uganda. The purpose is to enable
local herbal manufacturers to rise from baseline
regulatory compliance to sustained, predictive
practices. This maturity level matrix proposed consists
of 3 levels including Maturity level 3 (ML3 – the
existence of basic elements of the regulatory system),
Maturity Level 2 (ML2 – existence of more proactive
elements of regulatory systems), and Maturity level
1 (ML1 – the existence of continuous improvement
elements of regulatory system as shown in table 2. The
maturity level matrix is developed by categorizing all
GMP parameters based on risk analysis (probability
to cause cross-contamination and mix-ups) and
statistical correlation to overall non-compliance to
GMP guidelines as shown in table 3.
GMP parameters with low risk would constitute
Maturity Level 3 (ML3), with a stable and functioning
GMP system. GMP parameters ranked as the medium
risk would constitute the Maturity Level 2 (ML2),
with an evolving quality management system that
partially performs essential GMP functions as
regards Herbal products. All GMP parameters that are 
ranked high risk would constitute the Maturity Level
1 (ML1) and are considered essential for beinglisted
at all after assessment. Omitting any of these ML1
requirements constitutes a high risk to the final
consumer and cannot guarantee a good and consistent
quality product. See figure 4.
During the inspection, the checklist would be used for
assessing each GMP parameter. A maturity level
would then be assigned based on the maturity level
matrix. The ranking is valid as long as the facility
maintains this level of compliance. This ranking
would be subject to revision upon subsequent GMP
inspections. The list showing maturity level for
inspected local herbal manufacturers would then be
published on the NDA website.
5. CONCLUSION AND
RECOMMENDATIONS
From the results of the review of previous herbal
manufacturers’ GMP reports, it is clear that National
Drug Authority could do more work to improve the
herbal medicines sector in the country, as per its
mandate. The number of non-complying facilities
would have been higher if strict GMP classification of
the criticality of deficiencies was used during the
assessments. When conducting inspections, the NDA 
is also asked to consider the government policy“Buy
Uganda Build Uganda.” (Ministry of TradeIndustry
and Cooperatives, 2014) This is a policyto help 
indigenous businesses have a fair advantage for their




      
         
      
 
 








    
 
      
      
       
 
   
  
       
      
        
       
     
 
  
       
       
      





     
     
 
 
       
  
   
 
   
      
  
        
 
       
        




      
  
        
 
       
        





4: Schematic Model for Development of Risk-Based Herbal GMP Maturity Level Grading 
Low risk 
I 
1. Validation of assessment I 
checklist for reliabili ty 
• 
Used the Cronbach's alpha assessment to e valuate 
internal consistency of the tool . 
2 . Risk assessment of a l I 
paramet ers evaluated 
during GM P inspect ion 
Using the risk Matrix, each GMP 
parameter was ranked in terms of High 
risk, Medium risk and Low risk 
Assessed the parameters against risks of cross contamination 
and mix-up ;n relation to GMP and impact on the final product 
supplied to the patients. 
Using a Risk Matrix, risk scores were assigned to each GMP 
porometer for both cross contamination and Mix ups 
Medium risk High r isk 
Maturity Level 3 Maturity Level 2 
the regulator, instead of instituting enforcement
measures, is called on to help and guide the facility
to improve in their production processes when
nonconformance observations have been identified.
This weakens the effectiveness in enforcing the law,
thus allowing room for inferior quality products
to circulate on the market. However, if human and
financial resources are effectively utilized to train
local herbal manufacturers on GMP as well as set up
quality control infrastructure and establish quality
specifications for the different products and dosage
forms, the local herbal sector will greatly benefit and
take advantage of the indigenous flora to provide
alternative medicines to the population of Uganda.
Substantial improvements of the herbal   sector will
require intense sensitization of all relevant
stakeholders regarding the requirements for GMPand
the need to produce scientifically backed and
consistent products. Encouraging a culture of self- or
voluntary improvement through the introduction of
listing local herbal manufacturers, based on a maturity
level grading, will further encourage/motivate the
local manufacturers to invest resources in orderto
receive the recognition of the regulator, hence
increasing their reputation and business opportunities.
A limitation of the study was the small number of
GMPinspection reports for local herbal manufacturers
available for review. This reduced the desired
research population and, therefore, results may not be
generalizable. It is recommended to conduct a similar
analysis in the future to determine the outcomes of
analysis and compare those with the current results for
similarities or differences.
Integrate all aspects of quality, including Good 
Agricultural Practices, Good Processing Practices and
Good Manufacturing Practices in order to ensurethat 
products meet all pertinent the requirements. Any
deviations during the earlier stages of cultivation,
production, and manufacturing can adversely affect
the quality of the final products.
Additionally, there is a need to balance government
priorities of safeguarding the population of Uganda and 
helping indigenous manufacturers gain an advantage
under the Buy Uganda, Build Uganda (BUBU) policy.
The government could give protection to companies
that are committed to continuous improvement as
required by the law and discourage those only wanting 
to do the bare minimum or produce substandard
products that, instead, harm the general public.
Additionally, there is a need to balance government
priorities of safeguarding the population of Uganda and 
helping indigenous manufacturers gain an advantage
under the Buy Uganda, Build Uganda (BUBU) policy.
The government could give protection to companies
that are committed to continuous improvement as
required by the law and discourage those only wanting 
to do the bare minimum or produce substandard




             Table 3: Variables significantly associated with noncompliance to GMP guidelines requirements for Herbal manufacturers 
   using multivariate logistic regression
  Crude analysis  Adjusted analysis  Variables
  Crude OR  P-Value  Adjusted OR  P-Value
   Is there adequate space for equipment, materials and  Yes  1.0  -  1.0  -
     movement of personnel and materials?  No  3.25  0.002  4.81  0.001
        Are the premises constructed to allow adequate cleaning  Yes  1.0  -  1.0  -
      and good sanitation and hygiene practices?  No  8.71  0.012  7.12  0.041
          Is there a logical flow of activities, material and personnel?  Yes  1.0  -  1.0  -
 No  2.41  0.005  2.31  0.002
        Are raw materials or ingredients identified, inspected and  Yes  1.0  -  1.0  -
   tested before processing?  No  3.25  0.026  6.14  0.042
       Are there suitable weighing areas of materials?  Yes  1.0  -  1.0  -
 No  9.15  0.002  7.71  0.012
       Does the facility have appropriate weighing scales?  Yes  1.0  -  1.0  -
No  4.45  0.027  9.21  0.0002
  Are scales calibrated regularly?  Yes  1.0  -  1.0  -
No  7.25 0.042 8.31 0.031 
         Is the area for weighing frequently and adequately cleaned?  Yes  1.0  -  1.0  -
 No  8.15  0.042  5.61  0.028
          Is there a clear and illustrative procedure listing the required  Yes  1.0  -  1.0  -
    basic personal hygiene practices?  No  8.25  0.052  6.81  0.001
  Do the above facilities have running water for hand washing  Yes  1.0  -  1.0  -
  after use?  No  7.95  0.042  11.91  0.021
         Are Personnel protected from contact with toxic irritants and  Yes  1.0  -  1.0  -
   potentially allergenic plant materials by means of adequate
  protective clothing?  No  6.25  0.012  8.81  0.031
        Are batch manufacturing records kept for all batches?  Yes  1.0  -  1.0  -
 No  3.55  0.012  5.31  0.0016
   Is a record of sale and distribution of each batch of alterna-  Yes  1.0  -  1.0  -
 tive medicines maintained?  No  8.85  0.007  12.31  0.031
   Is the production area adequate enough to carry out pro-  Yes  1.0  -  1.0  -
  duction activities?  No  6.05  0.042  8.01  0.041
       Do all the personnel wear protective gear?  Yes  1.0  -  1.0  -
 No  4.26  0.018  6.21  0.045
         Are final products sampled batch wise for quality testing  Yes  1.0  -  1.0  -
   before being released?  No  7.65  0.039  9.21  0.003
        Does the facility have a quality control laboratory?  Yes  1.0  -  1.0  -
 No  9.23  0.027  13.01  0.014
        Is the final product correctly labelled including the expiry  Yes  1.0  -  1.0  -
 date?  No  5.17  0.002  8.51  0.031
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